Biotechnology
BioAtla's $40 million partnership with GATC Health to advance ozuriftamab vedotin into Phase 3 trials represents a sophisticated evolution in biotech financing and precision cancer therapeutics, with implications for both oncology and longevity research.
Biotechnology
T-MAXIMUM Pharmaceutical's MT027 receives FDA IND clearance for Phase II trials, marking a potential breakthrough in allogeneic CAR-T therapy for solid tumors and glioblastoma treatment.
Pharmaceuticals
January 2026 marks a pivotal month for pharmaceutical innovation with five critical FDA decisions that could transform patient care across rare diseases, oncology, and ophthalmology.
Biotechnology
The final days of 2025 delivered a devastating blow to Ultragenyx Pharmaceutical as the company lost over $1 billion in market value following the failure of its bone disease therapy setrusumab in two pivotal Phase III trials. The December 29 announcement that the drug failed to reduce fracture rates in
Biotechnology
AbbVie kicked off 2026 with a strategic bang, announcing a potentially $1.2 billion licensing deal with China's Suzhou Zelgen Biopharmaceuticals for exclusive rights to develop and commercialize alveltamig (ZG-006) outside of Greater China. The New Year's Eve agreement represents one of the largest T-
Biotechnology
FibroBiologics files IND application for CYPS317, marking the first fibroblast spheroid-based therapy to enter clinical development for psoriasis, with compelling preclinical data showing superior durability compared to existing biologic treatments.